<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665193</url>
  </required_header>
  <id_info>
    <org_study_id>H20-03225</org_study_id>
    <nct_id>NCT04665193</nct_id>
  </id_info>
  <brief_title>An Approach to Screening for COVID-19 at Vancouver Airport</brief_title>
  <official_title>An Approach to Screening for SARS-CoV-2 at YVR: UBC-PHC-WestJet-YVR COVID-19 Screening Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vancouver Airport Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WestJet Airlines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KLM Royal Dutch Airlines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study is to determine the feasibility and effectiveness&#xD;
      of a COVID-19 screening program for passengers departing from YVR. This research study is&#xD;
      conducted by The University of British Columbia (UBC) and Providence Health Care, sponsored&#xD;
      by WestJet and Vancouver Airport Authority. The experimental study investigates point-of-care&#xD;
      rapid test device for detecting SARS-CoV-2, the virus responsible for COVID-19. The study is&#xD;
      investigating a method of rapid-testing for COVID-19 and will help inform the safest and most&#xD;
      efficient way of testing departing passengers prior to security screening at Vancouver&#xD;
      International Airport (YVR). This study is also evaluating a new passenger management system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary of the Research Proposal&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      The purpose of this pilot study is to determine the feasibility and effectiveness of a&#xD;
      COVID-19 screening program at YVR for WestJet and KLM passengers.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      SARS-CoV-2 infection can be effectively screened using point-of-care rapid antigen assays.&#xD;
&#xD;
      Justification:&#xD;
&#xD;
      Passengers are required to wear masks and physically distance while traveling by air.&#xD;
      However, the majority of general public is still worried about the potential risk of&#xD;
      contracting COVID-19 on airplanes, especially during long flights. We need to develop methods&#xD;
      and strategies to quickly screen for SARS-CoV-2 infection, prior to boarding flights.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. To develop and deploy a management algorithm for COVID-19 screening at YVR that will&#xD;
           involve the use of point-of-care rapid test device.&#xD;
&#xD;
        2. To evaluate the acceptability of such screening algorithm and determine the costs of&#xD;
           deploying the program.&#xD;
&#xD;
      Research Design:&#xD;
&#xD;
      Study Population: Working in collaboration with WestJet and KLM we will invite all passengers&#xD;
      meeting Inclusion/Exclusion on outbound flights from YVR Airport to participate in this&#xD;
      study.&#xD;
&#xD;
      Phase 1: We will work with YVR and WestJet to enroll 200 subjects into the study. For this&#xD;
      initial phase we are looking to determine the rate of positivity in the cohort. This initial&#xD;
      phase is needed to evaluate the feasibility of this pilot program and to refine the initial&#xD;
      management algorithm. Health Canada-approved Panbio Covid-19 Ag Rapid Test Device by Abbott&#xD;
      Rapid Diagnostics (approved for Lab-based test and Point of care test on 2020-10-05) will be&#xD;
      uses in Phase 1.&#xD;
&#xD;
      Phase 2: Strategies for achieving higher-throughput will be determined after completion of&#xD;
      Phase 1. In phase 2, we will continue to work with YVR and WestJet, with the addition of KLM,&#xD;
      to enroll 700 subjects into the study. Phase 2 will further assess the efficiency of our&#xD;
      COVID-19 screening and passenger management algorithm.&#xD;
&#xD;
      The study is purposefully designed to be as minimally invasive to the passengers' travel plan&#xD;
      as possible. The Study Plans for Phase 1 and Phase 2 are detailed below.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      â€¢ When we aggregate the data for analysis, we will use basic statistics to determine mean,&#xD;
      variance, standard deviation, and positivity rate...etc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Actual">April 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 status</measure>
    <time_frame>15 minutes</time_frame>
    <description>positive or negative screening result</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">592</enrollment>
  <condition>Asymptomatic Condition</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Abbott Panbio test device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WestJet passengers departing from YVR screened for COVID-19 using Abbott Panbio test device</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid Antigen Test</intervention_name>
    <description>Antigen Technology Lab-based test and Point of care test</description>
    <arm_group_label>Abbott Panbio test device</arm_group_label>
    <other_name>Abbott Rapid Diagnostics Panbio Covid-19 Ag Rapid Test Device (Nasopharyngeal)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1 Inclusion Criteria:&#xD;
&#xD;
          1. The subject must be between 19 and 80 years of age.&#xD;
&#xD;
          2. The subject must be a resident of B.C.&#xD;
&#xD;
          3. The subject must have a ticket to board a WestJet flight departing from Vancouver&#xD;
             International Airport (YVR).&#xD;
&#xD;
          4. Have a minimum of 75 minutes of free time prior to the scheduled flight's departure.&#xD;
&#xD;
        Phase 2 Inclusion Criteria:&#xD;
&#xD;
          1. Subject has access to accommodation in Canada for safe-isolation as per public health&#xD;
             guidelines&#xD;
&#xD;
          2. Between the ages of 13 - 90&#xD;
&#xD;
          3. Travelling on any WestJet or KLM flight&#xD;
&#xD;
          4. Have a minimum of 70 minutes (if travelling within Canada) or 90 minutes (if&#xD;
             travelling International) of free time prior to the schedule flight's departure&#xD;
&#xD;
             -----------------------------------&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Subjects who have previously tested positive for COVID-19 within the past 90 days&#xD;
&#xD;
               -  Subjects who cannot provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Sin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Romney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver International Airport, WestJet Domestic Terminal, Level 3</name>
      <address>
        <city>Richmond</city>
        <state>British Columbia</state>
        <zip>V7B 0A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Don Sin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asymptomatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

